EGFR and breast cancer: We observed that the mutations/deletion of NEDD4L was mutually exclusive with the activation of AKT signaling pathway (PTEN deletion/mutations, epidermal growth factor receptor (EGFR), PI3KC, or AKT1 mutations/amplification) in breast cancers (Figure S6l, Supporting Information).